Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2013 - 2026)

Ocular Therapeutix has reported Total Non-Current Liabilities for 11 years, with the latest figure at $140.4 million in Q2 2026.

• Total Non-Current Liabilities for Q2 2026 came in at $140.4 million, up 6.83% year-over-year; the trailing twelve-month figure through Jun 2026 was $140.4 million (up 6.83% YoY), and the FY2025 annual result was $139.8 million, up 8.12% from the prior year.
• Total Non-Current Liabilities advanced to $140.4 million in Q2 2026, from $138.9 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $140.4 million in Q2 2026 and troughed at $94.6 million in Q1 2022.
• A 5-year average of $120.6 million and a median of $125.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The widest annual swing landed in 2023, when Total Non-Current Liabilities rose 29.53%; it then declined 5.08% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $107.6 million in 2022, then grew by 21.74% to $130.9 million in 2023, then declined by 1.22% to $129.3 million in 2024, then rose by 8.12% to $139.8 million in 2025, then increased by 0.37% to $140.4 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $140.4 million in Q2 2026, $138.9 million in Q1 2026, and $139.8 million in Q4 2025.